HLB Peptide Signs Personalized Cancer Peptide CDMO Agreement with Japan's Reprocell

Selected as the Key Manufacturer of Cancer Neoantigen-Targeted Peptides for Reprocell

On March 19, HLB Peptide announced that it has signed a supply agreement for patient-specific neoantigen peptide active pharmaceutical ingredients (APIs) with Reprocell, a Japanese cell therapy company.

HLB company logo image. HLB

Under this agreement, HLB Peptide will produce neoantigen-derived peptides for use in Reprocell’s personalized cancer therapies through a contract development and manufacturing organization (CDMO) model at its GMP-certified facility.

Neoantigen-based therapies involve analyzing each patient's genes to identify mutant proteins that exist only in cancer cells, and manufacturing peptides that specifically target these proteins. As these antigens are absent in normal cells, this approach is gaining attention as a targeted cancer treatment strategy.

HLB Peptide secured this agreement based on its capability to rapidly synthesize high-purity peptides tailored to each patient’s neoantigen sequence. In particular, the company believes its manufacturing capacity, which meets the stringent quality standards of the Japanese market, positions it to respond to growing global CDMO demand in the future.

The two companies plan to begin with the Japanese market and subsequently pursue global expansion. To meet the rising demand for CDMO services, HLB Peptide is also expanding its production facilities.

A representative from HLB Peptide stated, "This agreement demonstrates global recognition of our peptide manufacturing technology and GMP production capabilities," adding, "We will continue to expand our supply role in the field of personalized cancer therapies."

This content was produced with the assistance of AI translation services.